Atlas Trials

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Clinical trial NCT07132463 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07132463
Sponsor
Fudan University
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Rectal Cancer
Start date
2025-08-01
Primary completion
2027-12-01
Enrollment
154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.